- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim/Windsor, May 8, 2018 – In practice communications tools are an essential factor in helping manage vector-borne diseases in veterinary practice, debated an expert panel at the 13th CVBD® World Forum.
During the two-day forum, held in Windsor UK, low pet owner knowledge and poor adherence to regular preventative treatment for harmful vectors was identified as an important barrier to managing the global vector-borne disease burden.
With the role of the veterinarian being so important in overcoming this resistance, the forum argued that many vets may benefit from better communications tools to help facilitate more effective discussions regarding regular parasite prophylaxis with clients.
Driving the discussion within the forum was veterinarian Roeland Wessels, author of a published guide to communication strategies in veterinary practice. “We were trained as veterinarians to be the engineer of the animal body, but not necessarily in how to communicate effectively with pet owners,” Roeland explained. “As dogs and cats play a hugely beneficial role throughout our lives we should support the pet owner to provide their beloved pet the best levels of protection to ensure a happy and healthy life, especially with regards to preventative medicine and the prevention of vector-borne diseases”.
Specifically regarding vecor-borne disease prevention, veterinarians are encouraged to engage in dialogues with their clients on tailor-made strategies to better the wellness of their pet, rather than viewing parasiticide recommendation as a commercial obligation.
Asking open questions and employing active listening techniques were suggested by Roeland as useful tools to help veterinarians begin to facilitate this discussion more effectively and achieve a better understanding of clients' needs and barriers.
“Bayer is focused on ensuring the outputs of the CVBD® World Forum are meaningful for veterinarians in practical terms”, said Dr. Markus Edingloh, Head of Global Veterinary Scientific Affairs at Bayer Animal Health. “We will continue to support veterinarians with the resources to communicate with pet owners the importance of parasiticide products that reduce the risk of disease transmission, such as Seresto® and Advantix®.”
As part of the CVBD awareness campaign ‘It Only Takes One’, Bayer has developed a range of resources to help veterinarians communicate the risk of CVBDs to owners. These are available at www.CVBD.org
About CVBD® (Companion Vector-Borne Diseases) World Forum
Bayer Animal Health has continuously invested in raising awareness and education levels about Companion Vector-Borne Diseases (CVBDs) to protect dogs and cats around the world from harmful diseases. Every year, Bayer Animal Health brings together a global group of internationally renowned scientists to discuss latest findings and insights from research related to CVBDs.
About Companion Vector-Borne Diseases (CVBD®)
Companion vector-borne diseases (CVBD) are a growing international public health threat. These diseases are transmitted by blood-feeding ectoparasites, including ticks (Lyme disease, babesiosis, ehrlichiosis, anaplasmosis, and hemoplasmosis), fleas (bartonellosis and rickettsiosis), and sand flies (leishmaniosis). They are a known health hazard to animal and people around the world.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
Find more information at https://www.animalhealth.bayer.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.